GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Current Ratio

Merus Labs International (Merus Labs International) Current Ratio : 0.80 (As of Mar. 2017)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Merus Labs International's current ratio for the quarter that ended in Mar. 2017 was 0.80.

Merus Labs International has a current ratio of 0.80. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Merus Labs International has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Merus Labs International's Current Ratio or its related term are showing as below:

MSLI's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.87
* Ranked among companies with meaningful Current Ratio only.

Merus Labs International Current Ratio Historical Data

The historical data trend for Merus Labs International's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Current Ratio Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 1.28 1.05 2.41 0.77

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.80 0.77 0.83 0.80

Competitive Comparison of Merus Labs International's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Current Ratio distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Current Ratio falls into.



Merus Labs International Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Merus Labs International's Current Ratio for the fiscal year that ended in Sep. 2016 is calculated as

Current Ratio (A: Sep. 2016 )=Total Current Assets (A: Sep. 2016 )/Total Current Liabilities (A: Sep. 2016 )
=34.19/44.666
=0.77

Merus Labs International's Current Ratio for the quarter that ended in Mar. 2017 is calculated as

Current Ratio (Q: Mar. 2017 )=Total Current Assets (Q: Mar. 2017 )/Total Current Liabilities (Q: Mar. 2017 )
=34.979/43.532
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merus Labs International  (NAS:MSLI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Merus Labs International Current Ratio Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines